Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals Issued Key U.S. Patent for the Use of Asimadoline to Treat D-IBS
06.16.2011Tioga Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued Patent No.7,960,429 “KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME.” ...more
Tioga's lead product is asimadoline, a proprietary,
peripherally restricted small molecule kappa opioid agonist,
originally discovered by Merck KGaA of Darmstadt, Germany.
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
IBS is a common condition that is found in high prevalence throughout the world. Affected patients
experience recurrent episodes of abdominal pain or discomfort associated with a change in bowel pattern ...more